# Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection

> **NCT02363322** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 72 (actual)

## Conditions studied

- Ebola Virus Infection

## Interventions

- **DRUG:** B/Current Standard of Care Plus ZMapp
- **OTHER:** A/Current Standard of Care Alone

## Key facts

- **NCT ID:** NCT02363322
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-13
- **Primary completion:** 2017-12-31
- **Final completion:** 2017-12-31
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2019-06-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02363322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02363322, "Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02363322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*